Why did Cigna raise its 2026 outlook, and how confident should investors be in it?

Cigna raised its 2026 adjusted EPS outlook to at least $30.45 (+$0.10) and increased its Cigna Healthcare pre-tax outlook by $25 million to at least $4.55 billion. The raise reflects strong Cigna Healthcare margins and a lower SG&A ratio, and the outlook includes expected share repurchases and dividends. Management describes the figure as a floor ('at least'), but it excludes future net investment results, special items, and any acquisitions completed after the release date, so results could still vary materially.

Why did Evernorth's pharmacy benefit profit decline despite revenue growth?

Pharmacy Benefit Services adjusted revenues rose 8%, mainly from drug mix, but adjusted pre-tax income fell 27% to $609 million. Management attributed the decline to client-focused initiatives, including large client contract renewals, and to customer-focused initiatives. Evernorth overall still delivered a 2% decline in pre-tax income to $1.66 billion, partly offset by 22% growth in Specialty and Care Services.

What is the impact of Cigna's planned exit from Individual and Family Plans?

Cigna announced in April 2026 that it will exit the Individual and Family Plans medical business effective January 1, 2027. The release does not quantify the financial impact. The exit should reduce exposure to a business that drove prior-year risk adjustment benefits, and it is part of the company's effort to improve Cigna Healthcare margins. Investors should look for more detail in future filings on revenue and membership effects.

Why did GAAP net income grow more slowly than adjusted earnings?

GAAP shareholders' net income rose 8% to $6.29 per share, while adjusted EPS rose 8% to $7.78 (from $7.20). The gap between the two reflects special items, mainly $153 million in Q2 charges including strategic optimization program costs of $70 million and litigation charges of $77 million, as well as amortization of acquired intangibles of $296 million. Investors should review special items closely, since they recur in most quarters and can materially affect reported earnings.

CI 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) reported second quarter 2026 results on July 30, 2026, with total revenues up 7% year over year to $71.7 billion^a and shareholders' net income of $1.7 billion, or $6.29 per share, versus $5.71 in Q2 2025.

Adjusted income from operations rose 6% to $2.1 billion^b, or $7.78 per share, versus $7.20 a year earlier. The growth was driven mainly by Cigna Healthcare, where adjusted pre-tax income increased 17% on an improved U.S. Employer margin, while Evernorth Health Services' adjusted pre-tax income fell 2% as Pharmacy Benefit Services declined 27% on client and customer-focused initiatives. Specialty and Care Services grew adjusted pre-tax income 22%.

Management raised its full-year 2026 adjusted income from operations outlook to at least $30.45^c per share, up $0.10, and increased the Cigna Healthcare pre-tax outlook by $25 million to at least $4.55 billion. The Evernorth pre-tax outlook is at least $6.9 billion, and the Cigna Healthcare medical care ratio is guided to 83.7% to 84.7%. The SG&A expense ratio improved to 4.8% from 5.1%, reflecting operating efficiency.

The quarter also showed some top-line pressure. Total customer relationships fell 3%^d from year-end 2025 to 182.8 million, driven by a 4% decline in pharmacy customers from expected client transitions and lower health plan membership. Medical customers grew 2% to 18.4 million.

The company also announced in April 2026 its planned exit from the Individual and Family Plans medical business effective January 1, 2027. Through July 29, 2026, it repurchased 0.9 million shares for about $250 million.

02—Key points

Key Highlights

Q2 2026 total revenues rose 7% to $71.7 billion; adjusted revenues rose 7% to $71.6 billion, driven by Evernorth and Cigna Healthcare.
GAAP shareholders' net income was $1.66 billion ($6.29 per diluted share), up from $1.53 billion ($5.71) in Q2 2025; adjusted income from operations was $2.05 billion ($7.78 per share), up 6% from $7.20.
2026 adjusted EPS outlook raised to at least $30.45 (+$0.10), with Cigna Healthcare pre-tax outlook raised $25 million to at least $4.55 billion and Evernorth pre-tax outlook at least $6.9 billion.
Cigna Healthcare adjusted pre-tax income rose 17% to $1.28 billion with a 10.9% margin, driven by an improved U.S. Employer margin; the MCR was 84.5% versus 83.2% a year earlier due to a prior-year risk adjustment benefit in Individual and Family Plans.
Pharmacy Benefit Services adjusted pre-tax income fell 27% to $609 million on client contract renewals and customer-focused initiatives, while Specialty and Care Services grew adjusted pre-tax income 22% to $1.05 billion.
Total customer relationships declined 3% since year-end 2025 to 182.8 million, with pharmacy customers down 4% from client transitions and medical customers up 2% to 18.4 million.
SG&A expense ratio improved to 4.8% from 5.1% year over year, and the company repurchased 0.9 million shares for about $250 million year to date through July 29, 2026.

03—Questions

Frequently Asked Questions

Why did Cigna raise its 2026 outlook, and how confident should investors be in it?
Cigna raised its 2026 adjusted EPS outlook to at least $30.45 (+$0.10) and increased its Cigna Healthcare pre-tax outlook by $25 million to at least $4.55 billion. The raise reflects strong Cigna Healthcare margins and a lower SG&A ratio, and the outlook includes expected share repurchases and dividends. Management describes the figure as a floor ('at least'), but it excludes future net investment results, special items, and any acquisitions completed after the release date, so results could still vary materially.
Why did Evernorth's pharmacy benefit profit decline despite revenue growth?
Pharmacy Benefit Services adjusted revenues rose 8%, mainly from drug mix, but adjusted pre-tax income fell 27% to $609 million. Management attributed the decline to client-focused initiatives, including large client contract renewals, and to customer-focused initiatives. Evernorth overall still delivered a 2% decline in pre-tax income to $1.66 billion, partly offset by 22% growth in Specialty and Care Services.
Is the drop in customer relationships a concern?
Total customer relationships fell 3% to 182.8 million since December 31, 2025, mainly because pharmacy customers dropped 4% to 118.2 million. Management attributed the decline to expected client transitions and lower health plan membership. Medical customers grew 2% to 18.4 million, driven by Middle and Select markets. The pharmacy decline is largely tied to client transitions rather than a loss of competitive position, but investors should watch whether pharmacy membership stabilizes in coming quarters.
What is the impact of Cigna's planned exit from Individual and Family Plans?
Cigna announced in April 2026 that it will exit the Individual and Family Plans medical business effective January 1, 2027. The release does not quantify the financial impact. The exit should reduce exposure to a business that drove prior-year risk adjustment benefits, and it is part of the company's effort to improve Cigna Healthcare margins. Investors should look for more detail in future filings on revenue and membership effects.
Why did GAAP net income grow more slowly than adjusted earnings?
GAAP shareholders' net income rose 8% to $6.29 per share, while adjusted EPS rose 8% to $7.78 (from $7.20). The gap between the two reflects special items, mainly $153 million in Q2 charges including strategic optimization program costs of $70 million and litigation charges of $77 million, as well as amortization of acquired intangibles of $296 million. Investors should review special items closely, since they recur in most quarters and can materially affect reported earnings.

04—Continue

← View all 8-K filings